Adv Medical Solutns. - Full Year 2025 Trading Update

Advanced Medical Solutions

15/01/2026 07:00

RNS Number : 9445O

Advanced Medical Solutions Grp PLC

15 January 2026

 

15 January 2026

 

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

Full Year 2025 Trading Update

 

~ Strong growth in line with expectations, driven by key surgical product categories ~

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the innovative tissue-healing medical device company delivering high-performing solutions for better patient outcomes, today announces a trading update for the twelve months ended 31 December 2025.

The Group expects to report full year 2025 revenues of approximately £228.5 million (2024: £177.5 million), EBITDA of £49.5 - £50.0 million (2024: £40.2 million), and the Board is confident of meeting market expectations. Its performance was driven by continued strong growth across key surgical product categories and a good recovery in its Woundcare business, offsetting some elements of destocking in the Peters Surgical B2B business.

 

The integration of Peters Surgical and Syntacoll remains on track. Commercial synergies contributed positively during the year with operational synergies are on track to be realised during 2027 onwards.    

 

Notice of Results:

The Group intends to announce its full year results for the year ended 31 December 2025 on 18 March 2026.

 

Chris Meredith, Chief Executive Officer of AMS, said: "Our surgical business has recorded another period of strong performance, and we have also benefited from the restructuring of our woundcare franchise. Our portfolio is now broader and stronger than at any point in the Group's history, and our pipeline includes a number of exciting and significant opportunities for future growth. The integration of Peters Surgical has accelerated the expansion of our geographic footprint, and our plans for further penetration into the US market are well advanced. We remain confident in delivering another strong performance in 2026 and over the long-term, supported by the sustained momentum across the business." 

 

- End -

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc
Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Michael King, Investor Relations
Optimum Strategic Communications
Tel: +44 (0) 20 4566 8543
Mary Clark/ Nick Bastin / Isabelle Abdou
AMS@optimumcomms.com
Investec Bank PLC (NOMAD & Broker)
Tel: +44 (0) 20 7597 5970
Gary Clarence / David Anderson
Berenberg (Joint Broker)
Tel: +44 (0)20 3207 7800
Toby Flaux / Detlir Elezi


 

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is an innovative tissue healing medical device company delivering high-performing solutions that match or surpass market leaders, clinically, technically, and commercially. From adhesives and sealants, to biosurgical devices and sutures, AMS's products offer superior usability, quality and design. AMS's strength lies in combining advanced material science with applicator device design and development, in collaboration with surgeons and Key Opinion Leaders, creating differentiated devices that improve patient outcomes without compromising quality or affordability.

 

AMS's scalable, resilient business model is built on disciplined execution, portfolio focus, and capital efficiency. Its diversified product and geographic mix mitigates volatility, ensuring consistent performance even when individual segments fluctuate. Following its acquisition of Peters Surgical, AMS is unlocking operational and commercial synergies, accelerating its U.S. and international expansion, and increasing the percentage of sales made through its direct sales teams. With surgical products driving the lion's share of group revenues and a clear top-line trajectory, AMS is positioned for scalable growth, margin improvement, and long-term value creation.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
TSTBIMRTMTBBBTF